ADAR1 Capital Management, LLC
In its 13F for Q2 2025 (holdings as of June 30, 2025, filed August 14, 2025), ADAR1 Capital Management, LLC reported 192 stock positions worth $609.1 million. Its top holding was Keros Therapeutics (KROS) at 11.8% of the portfolio, followed by Protagonist Therapeutics (PTGX, 8.6%) and Alpha Architect 1-3 MNTH Box (BOXX, 6.2%). Compared with Q1 2025, it opened 40 new positions, sold out of 33, added to 62 and reduced 52. The biggest buy was Keros Therapeutics (KROS, shares +263%) and the biggest sale Roivant Sciences (ROIV, shares −44%).
- Most Recent 13F
- Q2 2026
- Location
- AUSTIN, TX
- CIK
- 0001940272
- Portfolio Value
- $609.1M (Q2 2025)
- SEC Filing
- 0001940272-25-000005 ↗ filed Aug 14, 2025
Holdings Value
Holdings 192 stocks · $609.1M
| KROS Keros Therapeutics Inc. | 11.81% | 5,389,264 | $71.9M | Add +262.6% |
| PTGX Protagonist Therapeutics Inc. | 8.60% | 948,069 | $52.4M | Add +0.9% |
| BOXX Alpha Architect 1-3 MNTH Box | 6.24% | 337,125 | $38.0M | No change |
| ZLAB Zai Lab Ltd.-ADR | 4.88% | 850,437 | $29.7M | Reduce -9.6% |
| ABVX Abivax SA-ADR | 3.86% | 3,071,340 | $23.5M | Add +39.0% |
| ROIV Roivant Sciences Ltd. | 3.59% | 1,940,797 | $21.9M | Reduce -44.3% |
| PRTA Prothena Corp. PLC | 3.36% | 3,375,009 | $20.5M | New |
| CYTK Cytokinetics Inc. | 3.16% | 582,147 | $19.2M | Add +49.0% |
| SPY SS SPDR S&P 500 ETF Trust-US | 2.30% | 22,684 | $14.0M | New |
| CGON CG Oncology Inc. | 2.23% | 523,216 | $13.6M | Add +73.8% |
| BIL SS SPDR BB 1-3M T-Bill ETF | 2.04% | 135,585 | $12.4M | No change |
| BBIO Bridgebio Pharma Inc. | 1.84% | 259,659 | $11.2M | Reduce -23.6% |
| IKT Inhibikase Therapeutics Inc. | 1.64% | 5,122,105 | $10.0M | No change |
| SEPN Septerna Inc. | 1.47% | 847,227 | $9.0M | Add +17.5% |
| ABUS Arbutus Biopharma Corp. | 1.43% | 2,825,773 | $8.7M | Add +50.4% |
| ETNB 89BIO Inc. | 1.41% | 875,983 | $8.6M | Add +8.9% |
| IMVT Immunovant Inc. | 1.41% | 535,066 | $8.6M | Reduce -44.8% |
| SVRA Savara Inc. | 1.35% | 3,600,670 | $8.2M | Add +164.7% |
| XENE Xenon Pharmaceuticals Inc. | 1.33% | 259,503 | $8.1M | Add +103.5% |
| BIOA Bioage Labs Inc. | 1.31% | 1,937,123 | $8.0M | Add +99.5% |
| FRNM Freenome Inc. filed as PERCEPTIVE CAP SOLUTIONS COR | 1.31% | 750,000 | $8.0M | No change |
| AMLX Amylyx Pharmaceuticals Inc. | 1.27% | 1,205,101 | $7.7M | Reduce -18.1% |
| CTMX Cytomx Therapeutics Inc. | 1.15% | 3,081,414 | $7.0M | Add +6451.2% |
| TSHA Taysha Gene Therapies Inc. | 1.14% | 3,009,870 | $7.0M | Add +182.3% |
| SAGE Sage Therapeutics Inc. | 1.08% | 721,599 | $6.6M | Reduce -2.8% |
| RAPT Rapt Therapeutics Inc. | 1.03% | 783,217 | $6.3M | New |
| AAM Aa Mission Acquisition Cor-A | 0.99% | 578,359 | $6.0M | No change |
| IONS Ionis Pharmaceuticals Inc. | 0.96% | 148,461 | $5.9M | New |
| TEVA Teva Pharmaceutical-SP ADR | 0.95% | 345,878 | $5.8M | Reduce -34.0% |
| OACCU Oaktree Acquisition III Life | 0.90% | 516,482 | $5.5M | No change |
| VERV Verve Therapeutics Inc. | 0.86% | 469,018 | $5.3M | New |
| RVMD Revolution Medicines Inc. | 0.81% | 134,136 | $4.9M | Reduce -24.3% |
| BBOT Bridgebio Oncology Therapeut filed as HELIX ACQUISITION CORP II | 0.77% | 442,615 | $4.7M | Reduce -5.8% |
| SHY iShares 1-3 Year Treasury Bo | 0.73% | 53,337 | $4.4M | Reduce -48.4% |
| RZLT Rezolute Inc. | 0.72% | 989,297 | $4.4M | Reduce -11.4% |
| MLYS Mineralys Therapeutics Inc. | 0.67% | 302,125 | $4.1M | Add +14.7% |
| CNTA Centessa Pharmaceuticals Ltd. | 0.64% | 296,766 | $3.9M | Add +37.3% |
| MNPR Monopar Therapeutics Inc. | 0.59% | 100,974 | $3.6M | Add +0.2% |
| SRPT Sarepta Therapeutics Inc. | 0.59% | 210,313 | $3.6M | Add +71.1% |
| ARDX Ardelyx Inc. | 0.59% | 915,130 | $3.6M | Add +86.5% |
| THRD Third Harmonic Bio Inc. | 0.56% | 622,873 | $3.4M | Add +522.9% |
| PCVX Vaxcyte Inc. | 0.52% | 98,032 | $3.2M | Add +665.9% |
| RYTM Rhythm Pharmaceuticals Inc. | 0.47% | 45,390 | $2.9M | Add +23.0% |
| VRNA Verona Pharma Ltd. | 0.44% | 28,450 | $2.7M | Add +42.3% |
| ALEC Alector Inc. | 0.40% | 1,723,526 | $2.4M | Add +353.2% |
| VRDN Viridian Therapeutics Inc. | 0.39% | 170,598 | $2.4M | Add +116.0% |
| ASPC A Spac III Acquisition Class A | 0.36% | 215,000 | $2.2M | No change |
| CRMD Cormedix Inc. | 0.35% | 175,000 | $2.2M | New |
| NAMS Newamsterdam Pharma Co. NV | 0.33% | 112,359 | $2.0M | New |
| DCTH Delcath Systems Inc. | 0.33% | 149,385 | $2.0M | No change |
| AVR Anteris Technologies Global | 0.33% | 531,515 | $2.0M | Reduce -68.3% |
| BPMC Blueprint Medicines Corp. | 0.32% | 15,000 | $1.9M | New |
| VKTX Viking Therapeutics Inc. | 0.29% | 67,813 | $1.8M | Add +14.1% |
| AKRO Akero Therapeutics Inc. | 0.29% | 33,143 | $1.8M | Reduce -53.4% |
| REGN Regeneron Pharmaceuticals | 0.29% | 3,361 | $1.8M | Add +146.9% |
| RGNX Regenxbio Inc. | 0.28% | 207,818 | $1.7M | Reduce -40.7% |
| DVAX Dynavax Technologies Corp. | 0.28% | 170,000 | $1.7M | No change |
| MLTX Moonlake Immunotherapeutics | 0.27% | 34,314 | $1.6M | Add +532.6% |
| ORKA Oruka Therapeutics Inc. | 0.26% | 142,780 | $1.6M | Add +7.5% |
| KNSA Kiniksa Pharmaceuticals Inte | 0.26% | 56,540 | $1.6M | Add +36.5% |
| CRNX Crinetics Pharmaceuticals Inc. | 0.25% | 53,125 | $1.5M | No change |
| TECX Tectonic Therapeutic Inc. | 0.24% | 73,505 | $1.5M | Add +17.4% |
| SLNO Soleno Therapeutics Inc. | 0.24% | 17,330 | $1.5M | Reduce -8.0% |
| JANX Janux Therapeutics Inc. | 0.24% | 62,088 | $1.4M | Reduce -59.6% |
| SRRK Scholar Rock Holding Corp. | 0.23% | 39,677 | $1.4M | Reduce -74.7% |
| ATXS Astria Therapeutics Inc. | 0.22% | 249,646 | $1.3M | Reduce -61.1% |
| ALKS Alkermes PLC | 0.21% | 45,000 | $1.3M | New |
| VIR Vir Biotechnology Inc. | 0.21% | 250,000 | $1.3M | No change |
| AGIO Agios Pharmaceuticals Inc. | 0.20% | 35,900 | $1.2M | Add +28.7% |
| CLDX Celldex Therapeutics Inc. | 0.19% | 57,466 | $1.2M | Add +293.6% |
| SWTX Springworks Therapeutics Inc. | 0.19% | 24,082 | $1.1M | Reduce -88.4% |
| ESTA Establishment Labs Holdings | 0.18% | 25,000 | $1.1M | Add +212.5% |
| ABOS Acumen Pharmaceuticals Inc. | 0.17% | 916,183 | $1.1M | Add +526.7% |
| CDTX Cidara Therapeutics Inc. | 0.17% | 21,522 | $1.0M | Add +2.8% |
| ZURA Zura Bio Ltd. | 0.17% | 997,547 | $1.0M | Reduce -64.4% |
| BSAAU Best Spac I Acquisition Corp. | 0.16% | 100,000 | $1.0M | New |
| ARGX Argenx SE - ADR | 0.16% | 1,759 | $970K | Add +193.2% |
| MRUS Merus NV | 0.16% | 18,313 | $963K | Reduce -72.7% |
| ALDX Aldeyra Therapeutics Inc. | 0.16% | 249,920 | $957K | Add +18.1% |
| PFE Pfizer Inc. | 0.16% | 39,400 | $955K | Reduce -4.0% |
| ARVN Arvinas Inc. | 0.16% | 128,767 | $948K | Reduce -58.9% |
| ACLX Arcellx Inc. | 0.15% | 13,962 | $919K | No change |
| NUVL Nuvalent Inc. Class A | 0.15% | 11,842 | $904K | New |
| TENX Tenax Therapeutics Inc. | 0.15% | 155,557 | $896K | Add +126.3% |
| SGRY Surgery Partners Inc. | 0.15% | 40,000 | $889K | No change |
| ARWR Arrowhead Pharmaceuticals Inc. | 0.14% | 55,200 | $872K | Reduce -1.9% |
| KRRO Korro Bio Inc. | 0.14% | 68,815 | $859K | Add +0.1% |
| KVACF Keen Vision Acquisition Corp. | 0.14% | 75,000 | $853K | New |
| VTGN Vistagen Therapeutics Inc. | 0.14% | 420,765 | $842K | No change |
| APGE Apogee Therapeutics Inc. | 0.13% | 18,070 | $785K | Reduce -82.8% |
| WVE Wave Life Sciences Ltd. | 0.12% | 114,814 | $746K | Add +397.0% |
| KALA Kala Bio Inc. | 0.12% | 149,830 | $713K | Reduce -49.9% |
| LRMR Larimar Therapeutics Inc. | 0.11% | 237,605 | $687K | New |
| RCKT Rocket Pharmaceuticals Inc. | 0.11% | 275,800 | $676K | Add +14.1% |
| KZR Kezar Life Sciences Inc. | 0.11% | 147,404 | $675K | No change |
| XNCR Xencor Inc. | 0.11% | 85,826 | $675K | Reduce -78.4% |
| CTNM Contineum Therapeutics Inc. Class A | 0.11% | 166,799 | $662K | Reduce -1.2% |
| BIIB Biogen Inc. | 0.11% | 5,100 | $641K | Add +13.3% |
| GERN Geron Corp. | 0.10% | 441,176 | $622K | Add +65.8% |
| PHAT Phathom Pharmaceuticals Inc. | 0.10% | 63,424 | $608K | Add +48.2% |
Options reported separately and not counted above: SPY puts ($25.0M), JANX calls ($6.1M), SMMT calls ($2.1M), SRPT calls ($941K), NKTR puts ($904K), BHVN calls ($353K), INMB puts ($301K), ATYR puts ($254K), DYN calls ($190K).
Other holdings (9): bonds, preferreds, convertibles and warrants · $6.8M (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| BRIDGEBIO PHARMA INC (BBIO 2.25 02/01/29) | NOTE 2.250% 2/0 · principal | 4,500,000 | $4.2M | No change |
| BRIDGEBIO PHARMA INC (BBIO 2.5 03/15/27) | NOTE 2.500% 3/1 · principal | 2,000,000 | $2.5M | No change |
| AAM.WS Aa Mission Acquisition -30 | *W EXP 08/01/203 | 505,099 | $50K | No change |
| ASPCR A Spac III Acquisition Corp. | RIGHT 01/02/2026 | 215,000 | $37K | No change |
| JVSAR Jvspac Acquisition Corp.-RTS | RIGHT 11/26/2026 | 24,000 | $21K | Reduce -20.0% |
| IROHR Iron Horse Acquisitions Righ | RIGHT 99/99/9999 | 12,320 | $6K | Reduce -50.7% |
| KVAWF Keen Vision Acquisition C-28 | *W EXP 03/15/202 | 75,000 | $4K | New |
| EMCRF Embrace Change Acq-Rights | RIGHT 10/25/2026 | 13,144 | $2K | No change |
| EMCWF Embrace Change Acquisitio-26 | *W EXP 10/25/202 | 18,000 | $360 | No change |
Total filed on the 13F, all lines: $615.9M.
Portfolio Sells Q1 2025 → Q2 2025
| ROIV Roivant Sciences Ltd. | Reduce -44.3% | 3.59% | −3.37 |
| IMVT Immunovant Inc. | Reduce -44.8% | 1.41% | −1.87 |
| ZLAB Zai Lab Ltd.-ADR | Reduce -9.6% | 4.88% | −1.85 |
| SWTX Springworks Therapeutics Inc. | Reduce -88.4% | 0.19% | −1.63 |
| RAPT THERAPEUTICS INC | Sold out | 0.00% | −1.44 |
| ITCI Intra-Cellular Therapies Inc. | Sold out | 0.00% | −1.25 |
| SHY iShares 1-3 Year Treasury Bo | Reduce -48.4% | 0.73% | −0.97 |
| AVR Anteris Technologies Global | Reduce -68.3% | 0.33% | −0.88 |
| SRRK Scholar Rock Holding Corp. | Reduce -74.7% | 0.23% | −0.77 |
| XNCR Xencor Inc. | Reduce -78.4% | 0.11% | −0.73 |
| AEROVATE THERAPEUTICS INC | Sold out | 0.00% | −0.73 |
| APGE Apogee Therapeutics Inc. | Reduce -82.8% | 0.13% | −0.65 |
| TEVA Teva Pharmaceutical-SP ADR | Reduce -34.0% | 0.95% | −0.64 |
| JANX Janux Therapeutics Inc. | Reduce -59.6% | 0.24% | −0.59 |
| ZURA Zura Bio Ltd. | Reduce -64.4% | 0.17% | −0.54 |
| PTCT PTC Therapeutics Inc. | Sold out | 0.00% | −0.50 |
| BBIO Bridgebio Pharma Inc. | Reduce -23.6% | 1.84% | −0.48 |
| ATXS Astria Therapeutics Inc. | Reduce -61.1% | 0.22% | −0.46 |
| RVMD Revolution Medicines Inc. | Reduce -24.3% | 0.81% | −0.43 |
| MRUS Merus NV | Reduce -72.7% | 0.16% | −0.40 |
| ARVN Arvinas Inc. | Reduce -58.9% | 0.16% | −0.28 |
| AKRO Akero Therapeutics Inc. | Reduce -53.4% | 0.29% | −0.28 |
| BBOT Bridgebio Oncology Therapeut | Reduce -5.8% | 0.77% | −0.28 |
| CRGX Cargo Therapeutics Inc. | Sold out | 0.00% | −0.28 |
| CKPT Checkpoint Therapeutics Inc. | Sold out | 0.00% | −0.24 |
| KALA Kala Bio Inc. | Reduce -49.9% | 0.12% | −0.22 |
| FULC Fulcrum Therapeutics Inc. | Reduce -89.1% | 0.06% | −0.22 |
| RGNX Regenxbio Inc. | Reduce -40.7% | 0.28% | −0.22 |
| ARES ACQUISITION CORP II | Sold out | 0.00% | −0.20 |
| KVAUF Keen Vision Acquisition Corp. | Sold out | 0.00% | −0.17 |
| CTNM Contineum Therapeutics Inc. Class A | Reduce -1.2% | 0.11% | −0.12 |
| ZYME Zymeworks Inc. | Sold out | 0.00% | −0.12 |
| INSM Insmed Inc. | Sold out | 0.00% | −0.09 |
| BNTX Biontech SE-ADR | Sold out | 0.00% | −0.09 |
| RNXT Renovorx Inc. | Reduce -95.9% | 0.00% | −0.09 |
| SAGE Sage Therapeutics Inc. | Reduce -2.8% | 1.08% | −0.09 |
| TIL Instil Bio Inc. | Sold out | 0.00% | −0.08 |
| ITOS Iteos Therapeutics Inc. | Reduce -73.4% | 0.04% | −0.08 |
| GPCR Structure Therapeutics Inc. | Reduce -57.9% | 0.05% | −0.07 |
| GRCE Grace Therapeutics Inc. | Reduce -48.6% | 0.09% | −0.07 |
| ISRG Intuitive Surgical Inc. | Sold out | 0.00% | −0.07 |
| DNTH Dianthus Therapeutics Inc. | Sold out | 0.00% | −0.07 |
| JVSA Jvspac Acquisition Corp. Class A | Sold out | 0.00% | −0.06 |
| KALV Kalvista Pharmaceuticals Inc. | Reduce -72.0% | 0.02% | −0.06 |
| JWN Nordstrom Inc. | Sold out | 0.00% | −0.06 |
| ANSC Agriculture & Natural Soluti | Reduce -42.5% | 0.05% | −0.05 |
| NTRA Natera Inc. | Reduce -41.2% | 0.07% | −0.05 |
| PFE Pfizer Inc. | Reduce -4.0% | 0.16% | −0.05 |
| SPRO Spero Therapeutics Inc. | Reduce -82.0% | 0.07% | −0.05 |
| MDGL Madrigal Pharmaceuticals Inc. | Reduce -29.3% | 0.05% | −0.05 |
Portfolio Buys Q1 2025 → Q2 2025
| KROS Keros Therapeutics Inc. | Add +262.6% | 11.81% | +8.81 |
| PRTA Prothena Corp. PLC | New | 3.36% | +3.36 |
| SPY SS SPDR S&P 500 ETF Trust-US | New | 2.30% | +2.30 |
| CTMX Cytomx Therapeutics Inc. | Add +6451.2% | 1.15% | +1.14 |
| ABVX Abivax SA-ADR | Add +39.0% | 3.86% | +1.12 |
| RAPT Rapt Therapeutics Inc. | New | 1.03% | +1.03 |
| IONS Ionis Pharmaceuticals Inc. | New | 0.96% | +0.96 |
| VERV Verve Therapeutics Inc. | New | 0.86% | +0.86 |
| TSHA Taysha Gene Therapies Inc. | Add +182.3% | 1.14% | +0.85 |
| CGON CG Oncology Inc. | Add +73.8% | 2.23% | +0.77 |
| SEPN Septerna Inc. | Add +17.5% | 1.47% | +0.64 |
| SVRA Savara Inc. | Add +164.7% | 1.35% | +0.60 |
| BIOA Bioage Labs Inc. | Add +99.5% | 1.31% | +0.59 |
| THRD Third Harmonic Bio Inc. | Add +522.9% | 0.56% | +0.49 |
| XENE Xenon Pharmaceuticals Inc. | Add +103.5% | 1.33% | +0.49 |
| PCVX Vaxcyte Inc. | Add +665.9% | 0.52% | +0.43 |
| CRMD Cormedix Inc. | New | 0.35% | +0.35 |
| NAMS Newamsterdam Pharma Co. NV | New | 0.33% | +0.33 |
| BPMC Blueprint Medicines Corp. | New | 0.32% | +0.32 |
| ALEC Alector Inc. | Add +353.2% | 0.40% | +0.30 |
| ETNB 89BIO Inc. | Add +8.9% | 1.41% | +0.25 |
| MLTX Moonlake Immunotherapeutics | Add +532.6% | 0.27% | +0.22 |
| ALKS Alkermes PLC | New | 0.21% | +0.21 |
| VRNA Verona Pharma Ltd. | Add +42.3% | 0.44% | +0.19 |
| VRDN Viridian Therapeutics Inc. | Add +116.0% | 0.39% | +0.18 |
| BSAAU Best Spac I Acquisition Corp. | New | 0.16% | +0.16 |
| NUVL Nuvalent Inc. Class A | New | 0.15% | +0.15 |
| ABOS Acumen Pharmaceuticals Inc. | Add +526.7% | 0.17% | +0.14 |
| KVACF Keen Vision Acquisition Corp. | New | 0.14% | +0.14 |
| CLDX Celldex Therapeutics Inc. | Add +293.6% | 0.19% | +0.14 |
| ABUS Arbutus Biopharma Corp. | Add +50.4% | 1.43% | +0.14 |
| REGN Regeneron Pharmaceuticals | Add +146.9% | 0.29% | +0.12 |
| LRMR Larimar Therapeutics Inc. | New | 0.11% | +0.11 |
| ARDX Ardelyx Inc. | Add +86.5% | 0.59% | +0.11 |
| ESTA Establishment Labs Holdings | Add +212.5% | 0.18% | +0.11 |
| PHVS Pharvaris NV | New | 0.10% | +0.10 |
| MRK Merck & Co. Inc. | New | 0.09% | +0.09 |
| ARGX Argenx SE - ADR | Add +193.2% | 0.16% | +0.09 |
| LUNG Pulmonx Corp. | New | 0.09% | +0.09 |
| WVE Wave Life Sciences Ltd. | Add +397.0% | 0.12% | +0.09 |
| RYTM Rhythm Pharmaceuticals Inc. | Add +23.0% | 0.47% | +0.08 |
| CDTX Cidara Therapeutics Inc. | Add +2.8% | 0.17% | +0.08 |
| SNY Sanofi-ADR | New | 0.08% | +0.08 |
| KNSA Kiniksa Pharmaceuticals Inte | Add +36.5% | 0.26% | +0.07 |
| AVTX Avalo Therapeutics Inc. | Add +947.3% | 0.09% | +0.07 |
| TENX Tenax Therapeutics Inc. | Add +126.3% | 0.15% | +0.06 |
| NKTR Nektar Therapeutics | Add +249.7% | 0.07% | +0.06 |
| CYTK Cytokinetics Inc. | Add +49.0% | 3.16% | +0.05 |
| JAZZ Jazz Pharmaceuticals PLC | New | 0.05% | +0.05 |
| PHAT Phathom Pharmaceuticals Inc. | Add +48.2% | 0.10% | +0.05 |
Options Activity Q1 2025 → Q2 2025
| SPY SS SPDR S&P 500 ETF Trust-US | put | New | 40,500 | $25.0M |
| NVS Novartis AG-Sponsored ADR | put | Sold out | 50,000 | $5.6Mbefore exit |
| SLNO Soleno Therapeutics Inc. | put | Sold out | 50,000 | $3.6Mbefore exit |
| SRPT Sarepta Therapeutics Inc. | call | New | 55,000 | $941K |
| NKTR Nektar Therapeutics | put | New | 35,000 | $904K |
| SWTX Springworks Therapeutics Inc. | call | Sold out | 15,000 | $662Kbefore exit |
| BHVN Biohaven Ltd. | call | New | 25,000 | $353K |
| INMB Inmune Bio Inc. | put | New | 130,200 | $301K |
| ATYR Atyr Pharma Inc. | put | New | 50,000 | $254K |
| DYN Dyne Therapeutics Inc. | call | New | 20,000 | $190K |
| PHAT Phathom Pharmaceuticals Inc. | call | Sold out | 10,100 | $63Kbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
Notes & Other Activity Q1 2025 → Q2 2025
| COHERUS ONCOLOGY INC (CHRS 1.5 04/15/26) | NOTE 1.500% 4/1 · principal | Sold out | 5,625,000 | $5.5Mbefore exit |
| BRIDGEBIO PHARMA INC | NOTE 1.750% 3/0 · principal | Sold out | 2,666,627 | $2.7Mbefore exit |
| JVSAR Jvspac Acquisition Corp.-RTS | RIGHT 11/26/2026 | Reduce -20.0% | 24,000 | $21K |
| IROHR Iron Horse Acquisitions Righ | RIGHT 99/99/9999 | Reduce -50.7% | 12,320 | $6K |
| KVAWF Keen Vision Acquisition C-28 | *W EXP 03/15/202 | New | 75,000 | $4K |
| UCFIW Iron Horse Acquisition Co.-29 | *W EXP 09/30/203 | Sold out | 25,000 | $800before exit |
Bonds, preferreds, convertibles and warrants; not part of the stock holdings or percentages above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 260 | $2.1B | ABVX, PTGX, ROIV, SPY, IMVT |
| Q1 2026 | 290 | $1.6B | ABVX, PTGX, ROIV, IMVT, SPY |
| Q4 2025Amended | 248 | $1.3B | ABVX, PTGX, ROIV, IMVT, RNAM |
| Q3 2025 | 196 | $1.0B | ABVX, KROS, PTGX, ROIV, BOXX |
| Q2 2025 | 192 | $609.1M | KROS, PTGX, BOXX, ZLAB, ABVX |
| Q1 2025 | 185 | $505.1M | PTGX, BOXX, ROIV, ZLAB, IMVT |
| Q4 2024 | 185 | $469.3M | ROIV, PTGX, BOXX, ZLAB, IMVT |
| Q3 2024 | 244 | $596.5M | CYTK, PTGX, BBIO, BOXX, ROIV |
| Q2 2024 | 231 | $496.6M | PTGX, CYTK, ROIV, BOXX, BBIO |
| Q1 2024 | 223 | $366.2M | BOXX, ROIV, ALNY, PTGX, CYTK |